To find cures for diseases and its complications for patients in neurology.
To improve patient’s lives by developing novel, best-in-class, state-of- care solutions using innovative drug delivery for unmet patient needs.
Avior is a clinical stage, pharmaceutical company developing drugs for distressed neurological conditions. Using its disruptive drug delivery technology – Speedit™ Transmucosal Film Technology – we are positioned to develop products that bring unsurpassed value in efficacy and safety. Avior has an excellent management team, strong advisory board, supportive partners, dedicated scientists and knowledgeable clinicians that position us to be successful.
Our lead product – AV104 – is designed the treatment of Prurigo Nodularis and chronic kidney disease associated pruritus.
In 2019, in response to the US Opioid crisis, and with support from the National Institute of Health, we added a second product – AV103 – with the intent to create a medical counter measure (MCM) for the reversal of opioid induced respiratory depression.
Develop drug delivery technologies that offer significant efficacy benefit and manufacturing cost advantage
Develop therapeutically differentiated drug products targeting new indications based on pharmacology
Target white space with patients with liver and kidney impairment
Create a strong “IP moat” around composition, process, and therapeutic application with barrier-to-entry position and trade secrets
Focus on improved pharmaco-economics in a payor-physician-patient-centric healthcare model
Innovative Drug Delivery. Improved Therapeutics.
Niraj Vasisht is the CEO at Avior. He has 25+ years of experience in the pharmaceutical industry from drug development to product launch. Prior to this, he was the Chief Technology Officer at Bio Delivery Sciences (Nasdaq: BDSI) where he co-led the development and approval of three commercial products – BELBUCA®, BUNAVAIL®, and ONSOLIS®. Along with the management team, Dr. Vasisht participated in raising approximately $160M in capital through equity, partnerships and debt financing. Prior to BDSI, Dr. Vasisht served as Director at Southwest Research Institute where he ran a small business unit and led a team of prolific researchers in product conceptualization, product development, engineering scale-up and commercial manufacturing across pharmaceutical, consumer health, and nutraceutical industry. There, he contributed to the early stage development of nutraceuticals (meg-3®), OTC (Citracal-D®), and a pharmaceutical Rx product (Probuphine®). He is a key-opinion-leader (KOL) in the field of delivery technologies. He is the inventor of 19 patents and many publications. He co-authored several book chapters and co-edited a reference book namely, “Microencapsulation for the Food Industry: A Practical Guide” (Elsevier). He sits on the Board of Defender Pharma and Mucodel Pharma. He received a Bachelor’s in Chemical Engineering from the Indian Institute of Technology, and a Ph.D. in Chemical Engineering from Rensselaer Polytechnic Institute.
Advisor – Clinical and Regulatory Affairs
Andrew Finn serves as an Advisor and Emeritus Chief Medical Officer at Avior. He has over 35+ years of experience in product development including clinical research (US and international), preclinical research, data management, statistics, regulatory affairs (US and European) and pharmaceutical development. Dr. Finn was the founder and Chief Operating Officer of Arius Pharmaceutical which was successfully acquired by BioDelivery Sciences (BDSI: Nasdaq) , and which later went on the develop and commercialize – BELBUCA®, BUNAVAIL®, and ONSOLIS®. Prior to BDSI, he was the Executive VP of Product Development at Pozen, and VP of Clinical Research at Solvay, and Director of Clinical Development at Glaxo. Dr. Finn has a Bachelor’s in Pharmacy from University of North Carolina -Chapel Hill and a Doctorate in Pharmacy from University of Michigan.
Advisor – Legal Affairs
Sanjeev Kumar serves as our General Counsel for Avior since April 2017 while serving as a partner in Hunt, Pennington, Kumar and Dula, PLLC. In his past, he served as a Chief Operating Officer of Portal Player (NASDAQ: PLAY) that was successfully acquire by NVIDIA. Mr. Kumar holds a Bachelor’s in Electric Engineering from Indian Institute of Technology, MS in Electrical Engineering from Tulane and a JD from St. Mary’s University School of Law.
Advisor – Preclinical Development
Dr. Christensen have over 20+ years of experience as a biotech executive managing pre-clinical discovery and pharmacology efforts across respiratory, inflammation, CNS, anti-infective, and oncology indications. He has been responsible for clinical trial design, biomarker development and toxicology study design. He is currently an Adjunct Associate Professor of Medicine (Hematology) at Duke University Medical Center and held senior positions at Oncotide, Cognosci, Affinergy Inc., Aryzun Pharmaceuticals, and KaroBio USA, formerly Novalon Pharmaceuticals. Dr. Christensen received his B.S. in Chemistry from Utah State University, and a Ph.D. in Organic Chemistry from the University of Utah. He was an NIH Postdoctoral Fellow at Texas A&M University. He has published many papers and is an inventor on numerous patents and patent applications in drug discovery.
Vice President – Formulation and Process Development
Dr. Taylor is the Vice President of Formulation and Process Development at Avior. He received his B.S. in Pharmacy from the University of North Carolina at Chapel Hill, B.S. in Chemical Engineering at North Carolina State University in Raleigh and his PhD in Pharmaceutics from the University of North Carolina at Chapel Hill. He has 30+ years of experience in Pharmaceutical R&D and Manufacturing Process Science with Merck, GlaxoSmithKline and BDSI. He is the Primary author on internal and external technical publications and patent applications. He is a Registered Pharmacist in North Carolina and serves as a Pharmaceutics lecturer, Research advisor and Graduate Thesis Committee at Campbell University School of Pharmacy as an Adjunct Associate Professor.